ResearcherNagoya University HospitalNo recent work listed
Yukio Ando
Matched on ORCID iD 0000-0001-7115-9105; OpenAlex author ID A5048279225. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 22
2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: none · 2022: 1 paper
Papers 4
- Selection of chemotherapy for older patients with pancreatic cancer based on geriatric assessment. Last author DOI 10.1016/j.jgo.2022.09.005↗
- Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic ductal adenocarcinoma (NUPAT 05 … Co-author DOI 10.18999/nagjms.81.2.233↗
- Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer. Co-author DOI 10.1007/s00280-018-3554-3↗
- Optimal dose of gemcitabine for the treatment of biliary tract or pancreatic cancer in patients with liver dysfunction. Last author DOI 10.1111/cas.12851↗
Closest collaborators
The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Osamu Maeda · 4 shared papers, 2016–2022 · strength 0.33
- Paper Selection of chemotherapy for older patients with pancreatic cancer based on geriatric assessment. DOI 10.1016/j.jgo.2022.09.005↗
- Paper Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pan… DOI 10.18999/nagjms.81.2.233↗
- Paper Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic c… DOI 10.1007/s00280-018-3554-3↗
- Hiroki Kawashima · 3 shared papers, 2018–2022 · strength 0.27
- Paper Selection of chemotherapy for older patients with pancreatic cancer based on geriatric assessment. DOI 10.1016/j.jgo.2022.09.005↗
- Paper Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pan… DOI 10.18999/nagjms.81.2.233↗
- Paper Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic c… DOI 10.1007/s00280-018-3554-3↗
- Takuya Ishikawa · 2 shared papers, 2019–2022 · strength 0.21
- Eizaburo Ohno · 2 shared papers, 2019–2022 · strength 0.21
- Masato Nagino · 3 shared papers, 2016–2019 · strength 0.19
- Paper Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pan… DOI 10.18999/nagjms.81.2.233↗
- Paper Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic c… DOI 10.1007/s00280-018-3554-3↗
- Paper Optimal dose of gemcitabine for the treatment of biliary tract or pancreatic cancer in patients with liver dysfunction. DOI 10.1111/cas.12851↗
- Masamichi Hayashi · 2 shared papers, 2018–2019 · strength 0.13
- Paper Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pan… DOI 10.18999/nagjms.81.2.233↗
- Paper Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic c… DOI 10.1007/s00280-018-3554-3↗
- Hidemi Goto · 2 shared papers, 2018–2019 · strength 0.13
- Paper Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pan… DOI 10.18999/nagjms.81.2.233↗
- Paper Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic c… DOI 10.1007/s00280-018-3554-3↗
- Nao Takano · 2 shared papers, 2018–2019 · strength 0.13
- Paper Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pan… DOI 10.18999/nagjms.81.2.233↗
- Paper Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic c… DOI 10.1007/s00280-018-3554-3↗
- Suguru Yamada · 2 shared papers, 2018–2019 · strength 0.13
- Paper Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pan… DOI 10.18999/nagjms.81.2.233↗
- Paper Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic c… DOI 10.1007/s00280-018-3554-3↗
- Shinji Naganawa · 2 shared papers, 2018–2019 · strength 0.13
- Paper Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pan… DOI 10.18999/nagjms.81.2.233↗
- Paper Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic c… DOI 10.1007/s00280-018-3554-3↗
- Junpei Yamaguchi · 2 shared papers, 2018–2019 · strength 0.13
- Paper Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pan… DOI 10.18999/nagjms.81.2.233↗
- Paper Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic c… DOI 10.1007/s00280-018-3554-3↗
- Yukihiro Yokoyama · 2 shared papers, 2018–2019 · strength 0.13
- Paper Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pan… DOI 10.18999/nagjms.81.2.233↗
- Paper Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic c… DOI 10.1007/s00280-018-3554-3↗
- Yasuhiro Kodera · 2 shared papers, 2018–2019 · strength 0.13
- Paper Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pan… DOI 10.18999/nagjms.81.2.233↗
- Paper Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic c… DOI 10.1007/s00280-018-3554-3↗
- Tsutomu Fujii · 2 shared papers, 2018–2019 · strength 0.13
- Paper Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pan… DOI 10.18999/nagjms.81.2.233↗
- Paper Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic c… DOI 10.1007/s00280-018-3554-3↗
- Yoshiki Hirooka · 2 shared papers, 2018–2019 · strength 0.13
- Paper Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pan… DOI 10.18999/nagjms.81.2.233↗
- Paper Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic c… DOI 10.1007/s00280-018-3554-3↗
- Masaya Suenaga · 1 shared paper, 2019 · strength 0.07
- Fuminori Sonohara · 1 shared paper, 2019 · strength 0.07
- Akihiro Hirakawa · 1 shared paper, 2019 · strength 0.07
- Ken-Ichi Fujita · 1 shared paper, 2016 · strength 0.06
- Takashi Shibata · 1 shared paper, 2016 · strength 0.06
- Yasutsuna Sasaki · 1 shared paper, 2016 · strength 0.06
- Tomoki Ebata · 1 shared paper, 2016 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.